Executive pay climbed again in 2025—and the CEO-to-worker gap kept widening

Elon Musk’s reinstated $158.4 billion Tesla stock award made him the highest-paid public company executive in fiscal 2025 by a wide margin, while excluding Musk, median CEO pay rose 13% to $4.75 million and the average climbed 26% to $8.96 million. The CEO-to-worker pay gap widened further, with the median ratio rising to 99-to-1 and Tesla posting the dataset’s highest ratio at 2,522,203-to-1. Equity-heavy pay packages dominated the top rankings across technology, real estate, health care, and EV-related companies.

Analysis

The main market signal is not the spectacle of Musk’s package, but the normalization of equity-linked pay across the upper end of the market. When boards keep setting compensation in stock rather than cash, they are implicitly choosing higher beta and more dilution to preserve cash flow; that tends to favor companies where management can credibly engineer multiple expansion, and it penalizes businesses already selling on narrative rather than operating leverage. The winners are names with enough market-cap scale and volatility to absorb large awards without immediate liquidity stress; the losers are the same companies if the equity market turns, because compensation becomes a second-order source of selling pressure and headline risk.

The more important read-through is governance dispersion. Tesla’s reinstated award reopens the playbook for founder-controlled structures, which can support long-duration capital allocation but also raises the probability of repeat litigation and advisory votes becoming more polarized. In the near term, that is a sentiment tailwind for high-profile, option-heavy growth names like FIG, OPEN, and SYM, where comp is effectively a statement of confidence. Over 6-12 months, though, the same structure can backfire if operating results do not keep up, because the market tends to punish dilution faster than it rewards incentive alignment.

The CFO and CTO data suggest an underlying labor-market bifurcation: finance compensation is still being bid up, while CIO pay is rolling over, implying boards are paying for external capital access and AI/product roadmaps while commoditizing back-office IT leadership. That favors companies with differentiated software, medical data, or automation layers and hurts incumbents whose digital spend is mostly defensive. In healthcare and real estate, the very large equity awards likely amplify execution pressure: WELL and SMMT need visible revenue or margin inflections within the next 2-3 quarters to justify the optics, or these packages become a governance overhang rather than an incentive.

The contrarian view is that the market may be underestimating dilution as a broad-based tax on future per-share returns. High stock-award compensation can coexist with strong headline growth, but if the issuance is persistent, it compresses future EPS and raises the hurdle for multiple expansion. In that sense, the more attractive relative value is not to chase the biggest comp headlines, but to own firms where management pay is aligned yet not outsized versus cash generation.

Key Decisions for Investors

• Long FIG / short a basket of high-dilution software names over 3-6 months: the market is likely to reward platform leaders with equity-fueled comp if growth remains intact, but FIG has cleaner governance optics and better operating leverage; target 15-20% relative outperformance if risk appetite holds.
• Short OPEN on a 1-3 month horizon via put spreads: the compensation headline increases execution scrutiny and dilution sensitivity in a name that still needs proof of sustainable unit economics; risk/reward favors downside if housing turnover stays sluggish.
• Long WELL vs short REITs with weaker capital-allocation credibility over 6-12 months: real estate is being rewarded for stock-based pay only when cash yields and growth are both visible; WELL can support the premium if acquisition and operating execution remain strong.
• Pair long HIMS / short HUM for 6-9 months: HIMS benefits from the market paying up for tech-enabled healthcare growth while HUM faces more compressed CIO/IT spending optics and lower narrative torque; use as a relative-growth-versus-defensive trade.
• Avoid chasing TSLA outright into the next board-cycle window; if already long, consider monetizing upside with covered calls over 1-2 months because governance litigation resolution reduces one overhang, but future dilution and headline volatility remain elevated.